[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100649815":3},{"organization":4,"armGroups":7,"interventions":31,"overallOfficials":46,"centralContacts":50,"locations":59,"responsibleParty":95,"collaborators":41,"id":97,"slug":98,"hasResults":99,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":41,"eligibilityCriteria":103,"healthyVolunteers":104,"sex":105,"minAge":106,"maxAge":107,"enrollmentInfo":108,"targetDuration":41,"studyType":111,"phases":112,"briefSummary":114,"conditions":115,"keywords":118,"overallStatus":62,"whyStopped":41,"lastUpdateSubmitDate":120,"lastUpdatePostDateStruct":121,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":129},{"fullName":5,"class":6},"Eli Lilly and Company","INDUSTRY",[8,15,19,22,25],{"label":9,"type":10,"description":11,"interventionNames":12},"Eloralintide Cohort 1","EXPERIMENTAL","Eloralintide administered subcutaneously (SC)",[13,14],"Drug: Eloralintide","Drug: Acetaminophen",{"label":16,"type":10,"description":17,"interventionNames":18},"Eloralintide Cohort 2","Eloralintide administered SC",[13,14],{"label":20,"type":10,"description":17,"interventionNames":21},"Eloralintide Cohort 3",[13,14],{"label":23,"type":10,"description":17,"interventionNames":24},"Eloralintide Cohort 4",[13,14],{"label":26,"type":27,"description":28,"interventionNames":29},"Placebo","PLACEBO_COMPARATOR","Placebo administered SC",[30,14],"Drug: Placebo",[32,39,42],{"type":33,"name":34,"description":35,"armGroupLabels":36,"otherNames":37},"DRUG","Eloralintide","Administered SC",[9,16,20,23],[38],"LY3841136",{"type":33,"name":26,"description":35,"armGroupLabels":40,"otherNames":41},[26],null,{"type":33,"name":43,"description":44,"armGroupLabels":45,"otherNames":41},"Acetaminophen","Administered Oral Solution",[9,16,20,23,26],[47],{"name":48,"affiliation":5,"role":49},"Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC\u002FGMT - 5 hours, EST)","STUDY_DIRECTOR",[51,56],{"name":52,"role":53,"phone":54,"phoneExt":41,"email":55},"Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or","CONTACT","1-317-615-4559","LillyTrials@Lilly.com",{"name":57,"role":53,"phone":41,"phoneExt":41,"email":58},"Physicians interested in becoming principal investigators please contact","clinical_inquiry_hub@lilly.com",[60,80],{"facility":61,"status":62,"city":63,"state":64,"zip":65,"country":66,"countryCode":67,"cosmosGeoPoint":68,"geoPoint":73,"contacts":74},"ICON Early Phase Services","RECRUITING","San Antonio","Texas","78209","United States","US",{"type":69,"coordinates":70},"Point",[71,72],-98.49363,29.42412,{"lat":72,"lon":71},[75,77],{"name":41,"role":53,"phone":76,"phoneExt":41,"email":41},"210-225-5437",{"name":78,"role":79,"phone":41,"phoneExt":41,"email":41},"Chinonye Ogbonnaya-Odor","PRINCIPAL_INVESTIGATOR",{"facility":81,"status":62,"city":82,"state":41,"zip":83,"country":82,"countryCode":84,"cosmosGeoPoint":85,"geoPoint":89,"contacts":90},"Lilly Centre for Clinical Pharmacology","Singapore","138623","SG",{"type":69,"coordinates":86},[87,88],103.85007,1.28967,{"lat":88,"lon":87},[91,93],{"name":41,"role":53,"phone":92,"phoneExt":41,"email":41},"+65 6413 9811",{"name":94,"role":79,"phone":41,"phoneExt":41,"email":41},"Greg Li",{"type":96,"investigatorFullName":41,"investigatorTitle":41,"investigatorAffiliation":41,"oldNameTitle":41,"oldOrganization":41},"SPONSOR","100649815","phase-1-a-study-of-eloralintide-ly3841136-in-participants-with-obesity-or-overweight-100649815",false,"NCT07738614","A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight","A Phase 1, Investigator- and Participant-Blinded, Placebo-Controlled, Randomized, Multiple-Dose Study to Evaluate the Gastric Emptying Delay, Pharmacokinetics, Safety, and Tolerability of Eloralintide in Participants With Obesity or Overweight","Inclusion Criteria:\n\n* Have overweight or obesity, but are otherwise overtly healthy.\n* Have a body mass index (BMI) within the range of 27.0 to 45.0 kilograms (kg)\u002Fsquare meter (m²), inclusive.\n* Have had a stable body weight, with less than 5 percent (%) change during the 3-month period prior to screening.\n\nExclusion Criteria:\n\n* Have been diagnosed with Type 1 or Type 2 diabetes mellitus, or have either of the following at screening\n\n  * A fasting plasma glucose concentration greater than or equal to 126 milligrams (mg)\u002Fdeciliter (dL) or 7.0 millimoles (mmol)\u002Fliter (L), or\n  * Hemoglobin A1C (HbA1c) greater than or equal to 6.5% or 48 mmol\u002Fmole (mol).\n* Have a history or presence of psychiatric disorders, including a history of major depressive disorder or severe psychiatric disorders such as schizophrenia, and bipolar disorder, within the last 2 years.\n* Have received a glucagon-like peptide-1 (GLP-1) receptor agonist, glucose-dependent insulinotropic polypeptide (GIP)\u002FGLP-1 receptor agonist, or GIP\u002FGLP-1\u002Fglucagon receptor agonist within 60 days or 5 half-lives, whichever is longer, prior to screening.\n* Are in the judgment of the investigator, actively suicidal or deemed to be at significant risk for suicide.",true,"ALL","18 Years","65 Years",{"count":109,"type":110},56,"ESTIMATED","INTERVENTIONAL",[113],"PHASE1","The main purpose of this study is to find out how significantly Eloralintide slows stomach emptying in participants who are overweight or obese. For each participant, the study will last approximately 21 weeks and will include 2 overnight stays in the clinical research unit (CRU) lasting between 4 and 8 days. There will be 13 other visits.",[116,117],"Obesity","Overweight",[119],"Healthy","2026-08-18",{"date":122,"type":123},"2026-08-20","ACTUAL",{"date":125,"type":123},"2026-07-31",{"date":127,"type":110},"2026-12",{"name":5,"class":6},2]